OBJECTIVE: To compare patient-reported limitations, concerns, and burdens in those receiving and not receiving warfarin for thromboprophylaxis in atrial fibrillation (AF). METHODS: We conducted a cross-sectional survey study of patients with AF receiving thromboprophylaxis for stroke prevention. Patients were administered the validated Anti-Clot Treatment Scale (ACTS). Mean scores of patients receiving and not receiving warfarin were compared for each ACTS item, and for the Burden and Benefit subscales. RESULTS: From July 2010 to August 2011, 80 patients with AF were administered the survey, with 65 patients receiving a regimen containing warfarin and 15 patients not receiving a regimen containing warfarin. Six of the 17 individual questions depicting patient- perceived limitations in physical activity due to bleeding, limitations on diet, feelings of inconvenience of occasional aspects of thromboprophylaxis therapy, and frustration, and burden had less favorable scores in the warfarin-managed patients compared with the patients not receiving warfarin (P < 0.05 for all). Mean ACTS Burden scores were more favorable in the no-warfarin group (44.5 ± 6.4) compared with the warfarin group (39.8 ± 8.0; P = 0.003). No difference was seen between the 2 groups on the ACTS Benefits score (11.1 ± 3.4 vs 10.4 ± 3.7; P = 0.38). CONCLUSION: Patients with AF receiving warfarin may have less favorable feelings regarding thromboprophylaxis versus those receiving non-warfarin thromboprophylaxis. Patients report having more limitations and having greater feelings of burden on warfarin.
OBJECTIVE: To compare patient-reported limitations, concerns, and burdens in those receiving and not receiving warfarin for thromboprophylaxis in atrial fibrillation (AF). METHODS: We conducted a cross-sectional survey study of patients with AF receiving thromboprophylaxis for stroke prevention. Patients were administered the validated Anti-Clot Treatment Scale (ACTS). Mean scores of patients receiving and not receiving warfarin were compared for each ACTS item, and for the Burden and Benefit subscales. RESULTS: From July 2010 to August 2011, 80 patients with AF were administered the survey, with 65 patients receiving a regimen containing warfarin and 15 patients not receiving a regimen containing warfarin. Six of the 17 individual questions depicting patient- perceived limitations in physical activity due to bleeding, limitations on diet, feelings of inconvenience of occasional aspects of thromboprophylaxis therapy, and frustration, and burden had less favorable scores in the warfarin-managed patients compared with the patients not receiving warfarin (P < 0.05 for all). Mean ACTS Burden scores were more favorable in the no-warfarin group (44.5 ± 6.4) compared with the warfarin group (39.8 ± 8.0; P = 0.003). No difference was seen between the 2 groups on the ACTS Benefits score (11.1 ± 3.4 vs 10.4 ± 3.7; P = 0.38). CONCLUSION:Patients with AF receiving warfarin may have less favorable feelings regarding thromboprophylaxis versus those receiving non-warfarinthromboprophylaxis. Patients report having more limitations and having greater feelings of burden on warfarin.
Authors: Miguel A Ruiz; José Ramón González-Porras; José Luis Aranguren; Eduardo Franco; Fernando Villasante; José Tuñón; Tomás José González-López; Marina de Salas-Cansado; Javier Soto Journal: Qual Life Res Date: 2016-12-18 Impact factor: 4.147
Authors: Carmen Suárez Fernández; Luis Castilla-Guerra; Jesus Cantero Hinojosa; Josep Maria Suriñach; Fernando Acosta de Bilbao; Juan José Tamarit; José Luis Diaz Diaz; Jose Luis Hernandez; Antonio Pose; Manuel Montero-Pérez-Barquero; Jaume Roquer; Jaime Gállego; José Vivancos; Jose María Mostaza Journal: Patient Prefer Adherence Date: 2018-02-19 Impact factor: 2.711
Authors: Shahrzad Salmasi; Adenike Adelakun; Abdollah Safari; Leanne Kwan; Jenny MacGillivray; Jason G Andrade; Marc W Deyell; Anita Kapanen; Peter Loewen Journal: CJC Open Date: 2021-06-29
Authors: Craig I Coleman; Sylvia Haas; Alexander G G Turpie; Silvia Kuhls; Susanne Hess; Thomas Evers; Pierre Amarenco; Paulus Kirchhof; A John Camm Journal: Clin Cardiol Date: 2016-06-30 Impact factor: 2.882
Authors: Leo Ungar; Fatima Rodriguez; Anne S Hellkamp; Richard C Becker; Scott D Berkowitz; Guenter Breithardt; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Christopher C Nessel; Daniel E Singer; Manesh R Patel; Jonathan P Piccini; Kenneth W Mahaffey Journal: Cardiol Ther Date: 2019-08-02